Erlotinib As Second-Line Therapy for Patients With Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors. J. Anal. Oncol. 2015, 4 (3),  94-101. https://doi.org/10.6000/1927-7229.2015.04.03.1.